Lun-Xiu Qin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8284505/publications.pdf

Version: 2024-02-01

		126907	144013
58	4,622 citations	33	57
papers	citations	h-index	g-index
60	60	60	5684
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics, 2022, 12, 260-276.	10.0	16
2	Pan-Cancer Analysis Reveals a Distinct Neutrophil Extracellular Trap-Associated Regulatory Pattern. Frontiers in Immunology, 2022, 13, 798022.	4.8	16
3	Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Reports, 2022, 39, 110712.	6.4	15
4	The combination of PD-1 blockade with interferon- \hat{l}_{\pm} has a synergistic effect on hepatocellular carcinoma. , 2022, 19, 726-737.		28
5	Left Hepatic Vein Preferential Approach Based on Anatomy Is Safe and Feasible for Laparoscopic Living Donor Left Lateral Sectionectomy. Liver Transplantation, 2021, 27, 88-95.	2.4	4
6	S100 calciumâ€binding protein A9 from tumorâ€associated macrophage enhances cancer stem cellâ€like properties of hepatocellular carcinoma. International Journal of Cancer, 2021, 148, 1233-1244.	5.1	45
7	Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics, 2021, 11, 6560-6572.	10.0	40
8	The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 249.	17.1	131
9	Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and l"Np63. Nature Communications, 2021, 12, 5232.	12.8	50
10	IFN- \hat{l}_{\pm} facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2021, 13, 301-313.	0.0	3
11	GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. Signal Transduction and Targeted Therapy, 2021, 6, 397.	17.1	58
12	Plasma circular RNA panel to diagnose hepatitis B virusâ€related hepatocellular carcinoma: A largeâ€scale, multicenter study. International Journal of Cancer, 2020, 146, 1754-1763.	5.1	83
13	Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. Journal of Hematology and Oncology, 2020, 13, 3.	17.0	163
14	MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming. British Journal of Cancer, 2020, 122, 209-220.	6.4	93
15	Isolation and characterization of exosomes for cancer research. Journal of Hematology and Oncology, 2020, 13, 152.	17.0	218
16	PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Frontiers in Immunology, 2020, 11, 589997.	4.8	45
17	The fuel and engine: The roles of reprogrammed metabolism in metastasis of primary liver cancer. Genes and Diseases, 2020, 7, 299-307.	3.4	12
18	Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Frontiers in Oncology, 2019, 9, 1104.	2.8	69

#	Article	IF	Citations
19	ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. Cell Metabolism, 2019, 29, 886-900.e5.	16.2	98
20	Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy. Cell Biology and Toxicology, 2019, 35, 407-421.	5.3	43
21	Core fucosylated glycan-dependent inhibitory effect of QSOX1-S on invasion and metastasis of hepatocellular carcinoma. Cell Death Discovery, 2019, 5, 84.	4.7	12
22	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut, 2019, 68, 1653-1666.	12.1	246
23	Long noncoding RNAs, emerging and versatile regulators of tumor-induced angiogenesis. American Journal of Cancer Research, 2019, 9, 1367-1381.	1.4	35
24	C chemokine receptor type 1 mediates osteopontinâ€promoted metastasis in hepatocellular carcinoma. Cancer Science, 2018, 109, 710-723.	3.9	28
25	Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2360-2368.	3.8	46
26	Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of \hat{l}^2 -Catenin. Cell Death and Disease, 2018, 9, 179.	6.3	44
27	FOXQ1/NDRG1 axis exacerbates hepatocellular carcinoma initiation via enhancing crosstalk between fibroblasts and tumor cells. Cancer Letters, 2018, 417, 21-34.	7.2	54
28	MicroRNA-219-5p Promotes Tumor Growth and Metastasis of Hepatocellular Carcinoma by Regulating Cadherin 1. BioMed Research International, 2018, 2018, 1-10.	1.9	20
29	RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis. Cellular Physiology and Biochemistry, 2018, 47, 1152-1166.	1.6	27
30	Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer. Tumor Biology, 2017, 39, 101042831769911.	1.8	14
31	Prosperoâ€related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating interleukinâ€8 expression. Hepatology, 2017, 66, 1894-1909.	7.3	31
32	Transcriptome integration analysis in hepatocellular carcinoma reveals discordant intronic miRNA-host gene pairs in expression. International Journal of Biological Sciences, 2017, 13, 1438-1449.	6.4	18
33	Erratum to Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients. Cancer Biology and Medicine, 2017, 14, 108-108.	3.0	0
34	Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients. Cancer Biology and Medicine, 2016 , 13 , 459 .	3.0	12
35	Properties and feasibility of using cancer stem cells in clinical cancer treatment. Cancer Biology and Medicine, 2016, 13, 489.	3.0	9
36	GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. Cancer Cell, 2016, 30, 444-458.	16.8	174

#	Article	IF	CITATIONS
37	Osteopontin Deficiency Alters Biliary Homeostasis and Protects against Gallstone Formation. Scientific Reports, 2016, 6, 30215.	3.3	8
38	Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis. World Journal of Gastroenterology, 2016, 22, 3038.	3.3	28
39	Integrative Genomic and Transcriptomic Characterization of Matched Primary and Metastatic Liver and Colorectal Carcinoma. International Journal of Biological Sciences, 2015, 11, 88-98.	6.4	37
40	The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Oncotarget, 2015, 6, 40068-40080.	1.8	12
41	\hat{l}^2 -catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Molecular and Clinical Oncology, 2015, 3, 936-940.	1.0	34
42	MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology, 2014, 59, 1874-1885.	7.3	177
43	Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. Surgery, 2014, 156, 651-660.	1.9	31
44	Genomic Aberrations in the HTPAP Promoter Affect Tumor Metastasis and Clinical Prognosis of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e90528.	2.5	1
45	Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology, 2013, 57, 1024-1034.	7.3	56
46	Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 3944-3954.	7.0	108
47	Inflammatory Immune Responses in Tumor Microenvironment and Metastasis of Hepatocellular Carcinoma. Cancer Microenvironment, 2012, 5, 203-209.	3.1	55
48	Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology, 2010, 52, 2012-2022.	7.3	45
49	Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology, 2008, 48, 1834-1842.	7.3	149
50	Postoperative interferon \hat{l}_{\pm} treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. Journal of Cancer Research and Clinical Oncology, 2006, 132, 458-465.	2.5	211
51	Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. Journal of Cancer Research and Clinical Oncology, 2004, 130, 497-513.	2.5	184
52	Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Medicine, 2003, 9, 416-423.	30.7	805
53	p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World Journal of Gastroenterology, 2002, 8, 459.	3.3	51
54	The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World Journal of Gastroenterology, 2002, 8, 193.	3.3	161

#	Article	IF	CITATION
55	The prognostic molecular markers in hepatocellular carcinoma. World Journal of Gastroenterology, 2002, 8, 385.	3.3	279
56	Chromosomal aberrations related to metastasis of human solid tumors. World Journal of Gastroenterology, 2002, 8, 769.	3.3	33
57	High-lose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology, 2000, 32, 43-48.	7.3	121
58	Effect of TT Virus Infection on Hepatocellular Carcinoma Development: Results of a Euroâ€Asian Survey. Journal of Infectious Diseases, 2000, 181, 1138-1142.	4.0	35